HeartBeam, Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics technology, bringing together two innovation leaders in ambulatory electrocardiogram (ECG) recording and analysis. The initial collaboration aims to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, available on HeartBeam’s devices.*
“This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring,” said Robert Eno, Chief Executive Officer of HeartBeam. “AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.”
HeartBeam’s groundbreaking credit card-sized, cable-free 3D ECG device captures the heart’s electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG using a personalized transformation matrix. HeartBeam plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software.
Also Read: Infinitus Unveils Trusted Voice AI Agents for Healthcare
Adding AccurKardia’s FDA-cleared, device-agnostic automated ECG interpretation platform to HeartBeam’s device will enhance HeartBeam’s subsequent commercial offering for arrhythmia assessment by enabling patients and physicians to get an automated rhythm assessment which will facilitate a quicker diagnosis and faster access to clinical care when needed. The strategic collaboration is expected to expedite HeartBeam’s product development efforts, reducing both costs and timelines.
“We believe combining AccurKardia’s device‑agnostic, FDA‑cleared automated ECG analytics with HeartBeam’s novel credit card‑sized device will be a true game‑changer that empowers patients to take charge of their cardiac health, wherever they are. By uniting our strengths, we’re creating a best‑in‑class platform that transforms how cardiac arrhythmia conditions are monitored and detected,” said Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia. “Putting clinical-grade ECG insights directly into a patient’s pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the United States.”
Source: Businesswire